{"id":39097,"title":"Novo Nordisk Faces Watchdog Rebuke Over Undisclosed UK Healthcare Payments","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2025-01-27T06:18:56+00:00","modified":"2025-01-27T06:18:56+00:00","canonical_url":"https://stockmark.it/novo-nordisk-faces-watchdog-rebuke-over-undisclosed-uk-healthcare-payments/","markdown_url":"https://stockmark.it/novo-nordisk-faces-watchdog-rebuke-over-undisclosed-uk-healthcare-payments.md","json_url":"https://stockmark.it/novo-nordisk-faces-watchdog-rebuke-over-undisclosed-uk-healthcare-payments.json","category":"Financial","categories":["Financial","Healthcare","Pharmaceutical"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/2022/11/uk-money-st.jpg?fit=800%2C400&quality=89&ssl=1","format":"news","language":"en-GB","content":"Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare sector payments spanning seven years.\n\nThe maker of weight-loss drug Wegovy was found to have misreported, under-reported, or completely omitted funding disbursed to pharmacy firms, obesity charities, training providers, professional bodies, and patient groups. The watchdog identified 48 breaches of industry code, highlighting serious compliance failures that occurred whilst the company was already under audit scrutiny.\n\nResearch conducted by academics at Bath and Lund universities revealed that even after Novo Nordisk’s internal review and claimed rectification, the company failed to accurately record payments totalling £635,000 to 30 organisations. These undisclosed transactions included a substantial £183,000 in funding to a weight-loss-coaching company partnering with pharmacies and the NHS.\n\nThe PMCPA’s ruling emphasises that these actions have “brought discredit upon, and reduced confidence in, the pharmaceutical industry.” The company had previously admitted to omitting over 500 transactions worth £7.8m between 2020 and 2022, leading to what the watchdog described as “fundamental governance failures.”\n\nIndustry experts are now calling for a comprehensive overhaul of pharmaceutical spending monitoring systems in Britain. Critics advocate for a government-run, centralised database with stringent enforcement mechanisms and penalties for non-compliance, moving beyond the current voluntary Disclosure UK scheme.\n\nNovo Nordisk responded by stating their dedication to transparent and ethical working practices, acknowledging the seriousness of these historical transfer disclosures. The company maintains its commitment to adhering to industry codes and upholding ethical standards, though this latest controversy adds to growing scrutiny over their promotional tactics for weight-loss medications."}